Drug Trial Radar · NCT07897188
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
425
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Dec 30, 2030
Study completion Nov 20, 2032
Sponsor
- Lead sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of ASKC202 combined with limertinib as the first-line treatment for locally advanced or metastatic NSCLC
Conditions
- EGFR Activating Mutation
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- MET Positive
Interventions
ASKC202Drug
ASKC202 tablets 200 mg QD
ASKC202 placeboDrug
ASKC202 placebo tablets QD
osimertinib placeboDrug
osimertinib placebo tablets QD
osimertinibDrug
osimertinib tablets 80 mg QD
pemetrexedDrug
pemetrexed 500 mg/m² by intravenous infusion on Day 1 of each 21-day cycle
cisplatin or carboplatinDrug
cisplatin 75 mg/m² or carboplatin (AUC 5) by intravenous infusion on Day 1 of each 21-day cycle for up to 4 cycles
LimertinibDrug
limertinib tablets 80 mg BID
limertinib placeboDrug
limertinib placebo tablets BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by BICRTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.